First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025.
“Grünenthal pioneered the research into NOP receptor agonists to deliver a unique and!-->…